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PD-1: programmed deathe1INTRODUCTION
Immune checkpoint inhibitors show remarkable
antitumor activity across multiple tumor types, with
approval of programmed deathe1 (PD-1) inhibitors
for nonesmall cell lung cancer and melanoma. A
recent clinical trial found median progression-free
survival of 11.5 months for combined nivolumab
plus ipilimumab therapy for metastatic melanoma
compared with 6.9 months (nivolumab alone) or
2.9 months (ipilimumab alone).1 Nivolumab, a fully
human IgG4 PD-1 antagonist antibody, and ipili-
mumab, a fully human IgG1 cytotoxic T-lympho-
cyteeassociated antigen 4 (CTLA-4) antagonist
antibody, act by relieving suppression of antitumor
T cells.
CTLA-4 inhibition (ipilimumab) potentiates early
T-cell activation during antigen presentation. PD-1
inhibition (nivolumab) acts primarily on T cells that
have already been activated and subsequently
suppressed via PD-1 signaling at sites of T cell
destination. Both CTLA-4 and PD-1 signaling nor-
mally dampen the immune system to protect
against excessive inflammation and development
of autoimmunity; however, in the setting of malig-
nancy, they can be co-opted by tumors to allow
immune evasion. Blocking such signaling has pro-
found antitumor effects in some patients.
Adverse effects associated with immune checkpoint
inhibitor therapy are termed immune-related
adverse events (irAEs) (Fig 1). Here we discuss a
rare irAE, sarcoidosis, in the setting of
combined ipilimumab/nivolumab therapy for lung
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ozzi@yale.edu.REPORT OF A CASE
A 60-year-old white woman with lung adenocar-
cinoma metastatic to her lymph nodes and brain,
receiving ipilimumab plus nivolumab for 7 months,
presented to her oncologist with nausea, vomiting,
aphasia, and confusion. She was admitted to the
hospital with differential diagnoses including
progressive brain metastases, radiation necrosis at
an intracranial site of prior radiosurgery, or an
adverse reaction to ipilimumab or nivolumab.
This patient was diagnosed with lung cancer
9 months prior after experiencing dysarthria and
worsening balance. Brain imaging found a left
frontal lobe lesion. Chest imaging uncovered a
right upper lobe lung mass with subcarinal and
paratracheal lymphadenopathy. Bronchoscopic bi-
opsy confirmed poorly differentiated lung adeno-
carcinoma, with histology findings negative for
epidermal growth factor receptor, anaplastic lym-
phoma kinase (ALK ) gene rearrangement, Kirsten
rat sarcoma viral oncogene homolog (KRAS) gene
mutation and human homolog of v-ROS avian UR2
sarcoma virus oncogene (ROS1) rearrangement.
She subsequently underwent uncomplicated
gamma knife surgery to the left frontal lobe brain
lesion.JAAD Case Reports 2016;2:264-8.
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Fig 1. The spectrum of immune-related adverse events reported with checkpoint inhibitor
therapy. The irAEs are graded based on severity from grade 1 to 4. Grade 2 to 3 reactions are
typically managed by temporarily withholding medication with or without systemic cortico-
steroids. Grade 4 or grade 3 reaction that recurs is indication for discontinuing medication.
Cutaneous irAEs can be managed with topical steroids if mild but may require systemic
corticosteroids with long tapers to prevent recurrence. (*) indicates irAE reported in the
literature in single case report. CN, Cranial nerve; GI, gastrointestinal.
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with ipilimumab every 6 weeks plus nivolumab
every 2 weeks (dosing for both drugs was 1 mg/kg)
according to trial protocol. Twoweeks into treatment
a mildly pruritic maculopapular rash developed; this
was diagnosed by her oncologist as ipilimumab-
associated cutaneous eruption and treated using oral
diphenhydramine and topical triamcinolone 0.1%
cream with resolution and no interruption in immu-
notherapy. Follow-up imaging per study protocol at
2 months found regression of cancer outside the
brain but also found progression of the left frontal
lobe lesion or treatment effect (ie, radiation necrosis).
Immunotherapy was held, and she underwent intra-
cranial resection, which found primarily radiation
necrosis. She restarted immunotherapy 2 weeks
after surgery, receiving a total of 3 ipilimumab and
10 nivolumab treatments prior to her current
presentation.
At presentation to the emergency room, her vital
signs were stable, but she was in diabetic ketoacidosis(serumglucose, 766mg/dL) andwas transferred to the
intensive care unit, where an insulin drip was started
and proved effective. On hospital day 7, the derma-
tologydepartmentwas consulted to evaluate a rash on
theneck.Onexamination, thepatient hadgreater than
fifty 1- to 3-mm skin-colored to pink firm papules,
some coalescing into annular plaques (Fig 2, A). Her
bilateral malar cheeks also had approximately 10 thin
pale pink 2- to 4-mm papules. Some papules had
umbilicated appearance. There was no apple jelly
color appreciated on diascopy. No cervical or axillary
lymphadenopathy or lacrimal gland hyperplasia was
appreciated. Skin biopsy of lesion on the posterior
neck revealed a dermal granulomatous infiltrate
consistent with sarcoidosis (Fig 2, B). A small focus
of polarizable material was seen. This finding was
noted in a previous case of ipilimumab-associated
cutaneous sarcoidosis.2 A diagnosis of cutaneous
sarcoidosis was made and was considered an irAE
secondary to ipilimumab, nivolumab, or the combi-
nation. She was treated with topical clobetasol 0.05%
Fig 2. Sarcoidosis in the setting of immune-related therapy for lung cancer. A, Distributed on
the posterior neck and upper arms are greater than fifty 1- to 3-mm skin-colored to pink firm
papules, in some areas coalescing into annular plaques. B, Dermal inflammatory infiltrate
including relatively scant lymphocytes and epithelioid histiocytes arranged in well-defined




266 Suozzi et alointment twice daily for 2 weeks with some
improvement but not resolution of the lesions. Brain
magnetic resonance imaging during the hospitaliza-
tion found interval increase in the left frontal
lobe metastasis, with sustained response to immuno-
therapy outside the brain. Subsequent intracranial
resection found metastatic lung adenocarcinoma.
The patient declined further treatment and died 3
months later.
DISCUSSION
Sarcoidosis is a rare irAE, with only 11 cases
reported to date (Table I). Most occurred during
ipilimumab treatment of metastatic melanoma, with
a single report (limited detail) of sarcoidosis with
antiePD-L1 antibody treatment. None have been
reported during treatment of lung cancer. Of these
cases, sarcoidosis occurred predominantly in the
lung (67% of the time) and less so in the skin
(25%). The timing of sarcoidosis onset ranged
anywhere from 2 cycles to 10 cycles of therapy.
There is evidence supporting a positive association
between irAEs and clinical response, specifically for
vitiligo during melanoma treatment13; however,
there does not seem to be a correlation between
development of sarcoidosis and treatment response
(Table I).
Sarcoidosis can be systemic, involving lung, skin,
central nervous system, or kidney.2,9 Clinicians
should be aware of the association between immu-
notherapy and sarcoidosis, because systemic
sarcoidosis can be mistaken for progression ofmalignancy on clinical examination and in imaging
studies. Fluorodeoxyglucose positron emission to-
mography/computed tomography (PET/CT), for
example, can highlight inflammatory cells in sarcoid-
osis and be misinterpreted as cancer progression.
This finding has the potential to adversely impact
decisions on patient treatment and management.
The diagnosis of sarcoidosis was delayed in many of
the cases analyzed in Table I because systemic
involvement was thought to represent progression
of malignancy. In our patient, when her brain mag-
netic resonance image showed an enlarging left
frontal lobe mass, systemic sarcoidosis was consid-
ered in the differential diagnosis and led to the
recommendation for definitive tissue sampling; un-
fortunately, in this instance, malignancy was
confirmed.
Our patient experienced 2 other adverse events
related to immunotherapy: macular papular cuta-
neous eruption, also called ipilimumab-associated
cutaneous eruption (discrete, erythematous, mini-
mally scaly, pruritic papules that can coalesce into
thin plaques, most often involving the trunk and
extremities) and insulin-dependent diabetes (in the
setting of PD-1 inhibition may develop over a time
ranging from 1 week to 5 months8,14). The rash
usually occurs early in treatment, 3 to 4 weeks after
the first dose, as occurred for our patient, and
responds to topical steroids.15 The rash can worsen
with subsequent cycles and be associated with a
significant increase in peripheral eosinophilia
(neither occurred in this patient).







sarcoidosis Drug Time into treatment, dose Response to treatment Study
67 y, F Melanoma (liver) Lung Ipilimumab 5 courses, q3w, 10 mg/kg Stable disease Eckert et al, 20093




Ipilimumab 6 courses q3w, 3 mg/kg Complete remission Vogel et al, 20124
— Prostate Lung (aveolar) Ipilimumab GVAX 1 ipi, 5 mg/kg q4w — van den Eertwegh
et al, 20125
52 y, F Melanoma (lung, LN) Lung Ipilimumab 2 courses, q3w, 3 mg/kg Progression of disease Wilgenhof et al, 20126
63 y, M Melanoma (lung,
liver, LN)
Lung Ipilimumab 4 cycles, q3w, 3 mg/kg Regression of mets Berthod et al, 20127
— Melanoma — AntiePD-L1 Ab 10 mg/kg, q2w — Brahmer et al, 20128
57 y, M Melanoma (LN) Lung, skin Ipilimumab 10 mg/kg, q3w x 4, then
q12w x 2
— Tissot et al, 20139
55 y, M Melanoma (LN) Lung, skin Ipilimumab 2 courses 10 mg/kg Developed cutaneous mets Reule and North, 20132
37 y, M Melanoma (LN, bone) Lung, CNS
(sella turcica)
Ipilimumab 4 courses, q3w, 3 mg/kg Sustained partial response Murphy, 201410
M Melanoma Spleen Ipilimumab — Sustained partial response Andersen et al, 201411
74 y, M Melanoma (liver) Granulomatous
interstitial nephritis
Ipilimumab 3 courses, 3 mg/kg Toumeh et al, 201512




10 cycles, 1 mg/kg Progression of disease Current case







































268 Suozzi et alCONCLUSION
With increased use of immune checkpoint in-
hibitors for cancer treatment, physicians are seeing a
variety of irAEs (Fig 1). In some cases, the irAE
provides insight into disease pathogenesis. For
example, validating findings in mice, it appears that
PD-1 inhibition unmasks genetic susceptibility to
diabetes.16 The pathomechanism of sarcoidosis is
poorly understood, but dysregulated cellular immu-
nity could play a key role through a T helpere1 T-
cellemediated response to an unknown antigen
(possibly mycobacterial),17,18 and this response
could be potentiated by checkpoint inhibitors. It is
not clear without further scientific research whether
specifically the ipilimumab or nivolumab (or both)
contributed to the pathogenesis of sarcoidosis in our
patient. If ipilimumab drives sarcoidosis alone, as it
may be in melanoma cases, our observation then
suggests the PD-1 pathway is either not involved, or
not able to abrogate, the CTLA-4 pathway effect.REFERENCES
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